{"protocolSection": {"identificationModule": {"nctId": "NCT01128569", "orgStudyIdInfo": {"id": "113090"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response", "officialTitle": "A Randomised, Double-blind, Placebo-controlled, Three-way Crossover, Repeat Dose Pilot Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination and Fluticasone Furoate on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-01"}, "primaryCompletionDateStruct": {"date": "2010-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-05-20", "studyFirstSubmitQcDate": "2010-05-20", "studyFirstPostDateStruct": {"date": "2010-05-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-06-06", "resultsFirstSubmitQcDate": "2013-09-05", "resultsFirstPostDateStruct": {"date": "2013-09-11", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-03-15", "dispFirstSubmitQcDate": "2012-03-15", "dispFirstPostDateStruct": {"date": "2012-03-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-30", "lastUpdatePostDateStruct": {"date": "2017-01-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from allergic triggers in asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["mild asthma", "allergen challenge", "early asthmatic response"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 52, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo Inhaler", "interventionNames": ["Drug: Placebo"]}, {"label": "inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)", "type": "ACTIVE_COMPARATOR", "description": "ICS/LABA inhaler", "interventionNames": ["Drug: FF/Vilanterol (VI; GW642444M)"]}, {"label": "ICS", "type": "ACTIVE_COMPARATOR", "description": "ICS inhaler", "interventionNames": ["Drug: Fluticasone Furoate"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone Furoate", "description": "FF", "armGroupLabels": ["ICS"], "otherNames": ["FF"]}, {"type": "DRUG", "name": "FF/Vilanterol (VI; GW642444M)", "description": "FF/VI", "armGroupLabels": ["inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)"], "otherNames": ["FF/VI"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo Inhaler", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants (par.) were exposed to an allergen (administered by inhalation) 22-23 hours after dosing on Day 28. FEV1 was measured 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours post-allergen challenge on Day 29. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1 were recorded at 1-minute intervals, and the best was taken as the post-saline value. The FEV1 weighted mean was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Weighted mean change from Baseline is calculated as the weighted mean FEV1 value on Day 29 minus the Baseline value. The Baseline FEV1 value was the post-saline value on Day 29.", "timeFrame": "Baseline and Day 29 of each treatment period (up to Study Day 197)"}], "secondaryOutcomes": [{"measure": "Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes (min) after inhalation of saline, 3 single measurements of FEV1were recorded at 1-min intervals, and the best was taken as the post-saline value. The maximum change (i.e., drop in FEV1) from post-saline Baseline (BL) is defined by ordering all of the change from BL values for the 5 min, 10 min, 15 min, 20 min, 30 min, and 45 min and the 1 hour, 1.5 hours, and 2 hours post-allergen challenge and selecting the largest change (i.e., drop in FEV1) from the BL value. If there were no negative change values, indicating a worse FEV1 value as compared to the BL value, the smallest change in FEV1, indicating an improvement from the BL value, was selected. The BL FEV1 value was the post-saline value on Day 29.", "timeFrame": "Baseline and Day 29 of each treatment period (up to Study Day 197)"}, {"measure": "Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1were recorded at 1-minute intervals, and the best was taken as the post-saline value. The minimum FEV1 over 0-2 hours post-allergen challenge (PAC) (minimum early asthmatic response) was the minimum value of all of the PAC time points up to and including 2 hours PAC (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours). Change from Baseline was calculated using the post-saline FEV1 on Day 29 as Baseline. Minimum FEV1 absolute change from Baseline between 0-2 hour, following the 22-23 hour post-treatment allergen challenge was calculated as the minimum change value on Day 29 minus the Baseline value", "timeFrame": "Baseline and Day 29 of each treatment period (up to Study Day 197)"}, {"measure": "Number of Participants With Treatment-emergent Adverse Events (AEs)", "description": "The number of participants with treatment-emergent AEs was measured. A treatment-emergent adverse event is defined as any event not present prior to the initiation of the treatments, or any event already present that worsens in either intensity of frequency following exposure to the treatments.", "timeFrame": "From the start of study medication until Follow-up/Early Withdrawal (up to 197 days)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2).\n* Females of non-child bearing potential.\n* Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation\n* Pre-bronchodilator FEV1 \\>70% of predicted at screening\n* Subjects who are current non-smokers\n* Methacholine challenge PC20 \\< 8 mg/mL at screening\n* Screening allergen challenge demonstrates that the subject experiences an early asthmatic response\n\nExclusion Criteria:\n\n* Current or chronic history of liver disease, or known hepatic or biliary abnormalities\n* Subject is hypertensive at screening\n* Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.\n* History of life-threatening asthma\n* Symptomatic with hay fever at screening or predicted to have symptomatic hayfever\n* Unable to abstain from short acting beta agonists\n* Unable to abstain from antihistamines\n* Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-asthma anti-rhinitis or hay fever medication\n* The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months\n* undergoing allergen desensitisation therapy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Berlin", "zip": "14050", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Wellington", "zip": "6021", "country": "New Zealand", "geoPoint": {"lat": -41.28664, "lon": 174.77557}}, {"facility": "GSK Investigational Site", "city": "London", "zip": "NW10 7EW", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}, "referencesModule": {"references": [{"pmid": "22738148", "type": "BACKGROUND", "citation": "Oliver A, Quinn D, Goldfrad C, van Hecke B, Ayer J, Boyce M. Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. Clin Transl Allergy. 2012 Jun 27;2(1):11. doi: 10.1186/2045-7022-2-11."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "113090", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113090", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113090", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113090", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113090", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113090", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "113090", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study was a multi-center, randomized, double-blind, placebo controlled, three-period crossover study in mild asthmatic male and female participants. Following the Run-in period, participants were randomized to 1 of 6 treatment sequences of placebo, FF 100 micrograms (\u00b5g) once daily (OD), and FF/VI 100/25 \u00b5g OD.", "recruitmentDetails": "Participants were screened within 42 days of the first dose, conducted over 2 days (not consecutive days). During this time, a methacholine challenge and an allergen challenge test were performed. Participants meeting all inclusion criteria and none of the exclusion criteria were randomized to 3 study treatment periods, each lasting 28 days.", "groups": [{"id": "FG000", "title": "Sequence 1: Placebo, FF 100 \u00b5g, FF/VI 100/25 \u00b5g", "description": "Participants received placebo, Fluticasone Furoate (FF) 100 micrograms (\u00b5g), and FF/Vilanterol (VI) 100/25 \u00b5g in Treatment Periods 1, 2, and 3, respectively. Participants received all treatments once a day (OD) in the evening from a Dry Powder Inhaler (DPI) for 28 days. The three treatment periods were separated by a washout period of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "FG001", "title": "Sequence 2: Placebo, FF/VI 100/25 \u00b5g, FF 100 \u00b5g", "description": "Participants received placebo, FF/VI 100/25 \u00b5g, and FF 100 \u00b5g in Treatment Periods 1, 2, and 3, respectively. Participants received all treatments once a day in the evening from a DPI for 28 days. The three treatment periods were separated by a washout period of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "FG002", "title": "Sequence 3: FF 100 \u00b5g, FF/VI 100/25 \u00b5g, Placebo", "description": "Participants received FF 100 \u00b5g, FF/VI 100/25 \u00b5g, and placebo in Treatment Periods 1, 2, and 3, respectively. Participants received all treatments once a day in the evening from a DPI for 28 days. The three treatment periods were separated by a washout period of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "FG003", "title": "Sequence 4: FF 100 \u00b5g, Placebo, FF/VI 100/25 \u00b5g", "description": "Participants received FF 100 \u00b5g, placebo, and FF/VI 100/25 \u00b5g in Treatment Periods 1, 2, and 3, respectively. Participants received all treatments once a day in the evening from a DPI for 28 days. The three treatment periods were separated by a washout period of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "FG004", "title": "Sequence 5: FF/VI 100/25 \u00b5g, Placebo, FF 100 \u00b5g", "description": "Participants received FF/VI 100/25 \u00b5g, placebo, and FF 100 \u00b5g in Treatment Periods 1, 2, and 3, respectively. Participants received all treatments once a day in the evening from a DPI for 28 days. The three treatment periods were separated by a washout period of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "FG005", "title": "Sequence 6: FF/VI 100/25 \u00b5g, FF 100 \u00b5g, Placebo", "description": "Participants received FF/VI 100/25 \u00b5g, FF 100 \u00b5g, and placebo in Treatment Periods 1, 2, and 3, respectively. Participants received all treatments once a day in the evening from a DPI for 28 days. The three treatment periods were separated by a washout period of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Treatment Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo, FF 100 \u00b5g OD, FF/VI 100/25 \u00b5g OD in 1 of 6 Sequences", "description": "All participants received one of the following three treatments in one of three treatment periods once daily (OD) in the evening from the Dry Powder Inhaler (DPI) for 28 days: Placebo, Fluticasone Furoate (FF) 100 microgram (\u00b5g) dry inhalation powder, and FF/Vilanterol (FF/VI) 100/25 \u00b5g dry inhalation powder. Participants were randomized to receive treatment in one of the six following sequences: (1) Placebo, FF 100 \u00b5g, FF/VI 100/25 \u00b5g; (2) Placebo, FF/VI 100/25 \u00b5g, FF 100 \u00b5g; (3) FF 100 \u00b5g, FF/VI 100/25 \u00b5g, Placebo; (4) FF 100 \u00b5g, Placebo, FF/VI 100/25 \u00b5g; (5) FF/VI 100/25 \u00b5g, Placebo, FF 100 \u00b5g; (6) FF/VI 100/25 \u00b5g, FF 100 \u00b5g, Placebo. The three treatment periods were separated by a washout period of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "52"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.4", "spread": "8.63"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "34"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}]}]}, {"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants (par.) were exposed to an allergen (administered by inhalation) 22-23 hours after dosing on Day 28. FEV1 was measured 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours post-allergen challenge on Day 29. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1 were recorded at 1-minute intervals, and the best was taken as the post-saline value. The FEV1 weighted mean was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Weighted mean change from Baseline is calculated as the weighted mean FEV1 value on Day 29 minus the Baseline value. The Baseline FEV1 value was the post-saline value on Day 29.", "populationDescription": "Intent-to-Treat (ITT) Population: par. randomized to treatment who received \\>=1 dose of study drug. Only those par. available at the specified time points were analyzed. Analysis was performed using mixed model analysis of covariance (ANCOVA) with fixed effects of treatment, period, par.-level Baseline, period level Baseline, country, sex, and age.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Day 29 of each treatment period (up to Study Day 197)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received Placebo OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received FF 100 \u00b5g dry inhalation powder OD in the evening from the DPI for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g dry inhalation powder OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.372", "spread": "0.0557"}, {"groupId": "OG001", "value": "-0.210", "spread": "0.0549"}, {"groupId": "OG002", "value": "-0.227", "spread": "0.0550"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "0.162", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.087", "ciUpperLimit": "0.237"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "0.145", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.069", "ciUpperLimit": "0.222"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.091", "ciUpperLimit": "0.057"}]}, {"type": "SECONDARY", "title": "Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes (min) after inhalation of saline, 3 single measurements of FEV1were recorded at 1-min intervals, and the best was taken as the post-saline value. The maximum change (i.e., drop in FEV1) from post-saline Baseline (BL) is defined by ordering all of the change from BL values for the 5 min, 10 min, 15 min, 20 min, 30 min, and 45 min and the 1 hour, 1.5 hours, and 2 hours post-allergen challenge and selecting the largest change (i.e., drop in FEV1) from the BL value. If there were no negative change values, indicating a worse FEV1 value as compared to the BL value, the smallest change in FEV1, indicating an improvement from the BL value, was selected. The BL FEV1 value was the post-saline value on Day 29.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed. Analysis was performed using mixed model analysis of covariance (ANCOVA) with fixed effects of treatment, period, participant-level BL, period level BL, country, sex, and age. Change from BL was calculated as the value on Day 29 minus the BL value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Day 29 of each treatment period (up to Study Day 197)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received Placebo OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received FF 100 \u00b5g dry inhalation powder OD in the evening from the DPI for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g dry inhalation powder OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-24.991", "spread": "2.0736"}, {"groupId": "OG001", "value": "-14.040", "spread": "2.0435"}, {"groupId": "OG002", "value": "-13.206", "spread": "2.0491"}]}]}]}, {"type": "SECONDARY", "title": "Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1were recorded at 1-minute intervals, and the best was taken as the post-saline value. The minimum FEV1 over 0-2 hours post-allergen challenge (PAC) (minimum early asthmatic response) was the minimum value of all of the PAC time points up to and including 2 hours PAC (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours). Change from Baseline was calculated using the post-saline FEV1 on Day 29 as Baseline. Minimum FEV1 absolute change from Baseline between 0-2 hour, following the 22-23 hour post-treatment allergen challenge was calculated as the minimum change value on Day 29 minus the Baseline value", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed. Analysis was performed using mixed model ANCOVA with fixed effects of treatment, period, participant-level Baseline, period level Baseline, country, sex, and age.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Day 29 of each treatment period (up to Study Day 197)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received Placebo OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received FF 100 \u00b5g dry inhalation powder OD in the evening from the DPI for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g dry inhalation powder OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.809", "spread": "0.0775"}, {"groupId": "OG001", "value": "-0.479", "spread": "0.0765"}, {"groupId": "OG002", "value": "-0.478", "spread": "0.0767"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-emergent Adverse Events (AEs)", "description": "The number of participants with treatment-emergent AEs was measured. A treatment-emergent adverse event is defined as any event not present prior to the initiation of the treatments, or any event already present that worsens in either intensity of frequency following exposure to the treatments.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From the start of study medication until Follow-up/Early Withdrawal (up to 197 days)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received Placebo OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from the Day 28 dose) and a maximum of 35 days."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received FF 100 \u00b5g dry inhalation powder OD in the evening from the DPI for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g dry inhalation powder OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "51"}, {"groupId": "OG002", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "18"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up/Early Withdrawal (up to 197 days).", "description": "SAEs and non-serious AEs were reported for members of the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received Placebo OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from the Day 28 dose) and a maximum of 35 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 15, "otherNumAtRisk": 51}, {"id": "EG001", "title": "FF 100 \u00b5g OD", "description": "Participants received FF 100 \u00b5g dry inhalation powder OD in the evening from the DPI for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 18, "otherNumAtRisk": 51}, {"id": "EG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/VI 100/25 \u00b5g dry inhalation powder OD from the DPI in the evening for 28 days during one of the three treatment periods. Each treatment period was followed by a washout of at least 21 days (from Day 28 dose) and a maximum of 35 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 11, "otherNumAtRisk": 51}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 51}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 51}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 51}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 51}]}, {"term": "Mouth ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 51}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 51}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 51}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 51}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Clinic visit", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}